Dengue fever, often known as breakbone or dandy fever, was estimated to have caused 1.5 million cases worldwide by the middle of 2020. According to WHO statistics, the number of reported cases is steadily growing. More than 2.38 million cases of dengue fever were reported in the Americas, with 1.5 million cases reported by Brazil alone, about three times the number reported in 2014. Hence, increasing prevalence of dengue led to the introduction of dengue treatment in the market.
Data Bridge Market Research analyses that the Dengue Treatment Market is expected to grow at a CAGR of 25.5% in the forecast period of 2021 to 2028 and is expected to reach USD 3,048.63 million by 2028.
Key Findings of the Study
- The dengue treatment market is anticipated to reach a value of USD 3,048.63 million by 2028, with a CAGR of around 25.5% during the forecast period from 2021 to 2028.
- North America dominated the dengue treatment market in 2021 due to rising number of outsourcing services and surging research and development activities in pharma and biotech sector in this region.
- Asia Pacific is expected to register lucrative growth over the forecast period of 2021 to 2028 owing to rapid urbanization and laboratory automation in this region.
- The mosquito-to-human segment accounted for the largest share in 2021 at 96.1%. Mosquitoes are the principal vectors of dengue virus transmission for the various strains of the virus which is expected to boost the dengue treatment market growth.
- The dengue treatment market was positively affected by COVID-19 outbreak. In the early stages of infection, dengue viruses and the virus that causes COVID-19 (SARS-CoV-2) have comparable symptoms. This resulted in high testing and treatment demand.
Increase in Incidences of Dengue is Expected to Drive the Market's Growth Rate
The increasing incidences of dengue illnesses and the increase in the number of awareness initiatives to teach about the afflictions of dengue are the primary drivers driving market expansion. Over the last few years, the general incidence of dengue fever and the severity of outbreak have risen considerably. According to the Pan American Health Organization, a total of 3,139,335 cases of dengue fever were reported in the Americas Region in 2019, equating to 321.58 cases per 100,000 people and 1,538 deaths. According to the same source, 1,367,353 cases were laboratory confirmed, with 28,169 categorized as severe dengue.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2018 - 2013)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Strains (DENV-1, DENV-2, DENV-3, DENV-4, Others), Transmission (Mosquito-to-Human Transmission and Mother-to-Child Transmission), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Mylan N.V. (US), Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Sanofi (France), GlaxoSmithKline plc (US), Dr. Reddy’s Laboratories Limited(Hyderabad) Fresenius Kabi (USA), Baxter(US), Perrigo Company plc (Ireland), ABIVAX (France), EMERGEX VACCINES (UK), Hikma Pharmaceuticals PLC (UK), Takeda Pharmaceutical Company Limited (Japan)
|
|
Data Pointers Covered in Report
|
The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The dengue treatment market is segmented on the basis of strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel.
- On the basis of strains, the dengue treatment market is segmented into DENV-1, DENV-2, DENV-3, DENV-4, others. In 2021, DENV-2 segment is dominating the market with 60.1% market share as this strain has a high global prevalence, resulting in more occurrences of dengue fever illness.
- On the basis of transmission, the dengue treatment market is segmented into mosquito-to-human transmission and mother-to-child transmission. In 2021, mosquito-to-human transmission segment is dominating in the market with 96.1% market share as the mosquitoes are the principal vectors of dengue virus transmission for the various strains of the virus.
In 2021, the Mosquito-to-Human Segment is Projected to Hold the Largest Share of Distribution Channel Segment in the Dengue Treatment Market
In 2021, the mosquito-to-human segment is anticipated to hold the largest share of global dengue treatment market as the mosquitoes are the principal vectors of dengue virus transmission for the various strains of the virus. The mosquito-to-human segment is growing with a CAGR of 25.6% in the forecast period of 2021 to 2028.
- On the basis of type, the dengue treatment market is segmented into medication, supportive care, vaccination and others. In 2021, medication segment is dominating in the market with 74.2% market share because for a long time, a range of medications used to treat dengue fever have been utilized to treat the disease.
- On the basis of severity, the dengue treatment market is segmented into uncomplicated and severe. In 2021, uncomplicated segment is dominating in the market with 92.9% market share because the conversion rate of uncomplicated to severe dengue is less than 5%, which is one of the main reasons why the uncomplicated category dominates the dengue treatment market.
In 2021, the Uncomplicated Segment of Application Segment is Anticipated to Dominate the Dengue Treatment Market
In 2021, the uncomplicated segment of this market will dominate the dengue treatment market because the conversion rate of uncomplicated to severe dengue is less than 5%, which is one of the main reasons why the uncomplicated category dominates the dengue treatment market. The uncomplicated segment is expected reach the highest CAGR of 25.7% in the forecast period of 2021-2028.
- On the basis of route of administration, the dengue treatment market is segmented into oral and parenteral. In 2021, the oral segment is dominating in the market with 73.0% market share because for pain relief and fever control, most of the medications used to treat dengue symptoms are taken orally.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and over the counter (OTC). In 2021, prescription segment is dominating in the market with 77.9% market share as the doctors prescribe medication and supportive care after confirming that the patient has been infected with the dengue virus, and treatment choices include antibiotics and other medications that are often not available as prescription medication solely.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market with 70.5% market share because after the diagnosis of dengue fever, the symptoms can be treated at home using medications such as pain relievers and fever reducers.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market with 75.2% market share as after a proper diagnosis of dengue fever, the majority of patients' prescriptions are filled in retail pharmacies for the course of the infection's treatment cycle.
Major Players
Data Bridge Market Research recognizes the following companies as the major dengue treatment market players in dengue treatment market are Baxter (US), Hikma Pharmaceuticals PLC (UK), and Aurobindo Pharma (Hyderabad).
Market Development
- In December 2021, Kao Corporation had announced the launch of campaign reduce the spread of dengue fever. Kao has used its original technology to develop similar products as part of the initiative. Kao distributed 80,000 units of the product in partnership with the Thai Ministry of Public Health, and donated 6.5 million Thai baht to the Ministry in total, which includes the items. In addition, the initiative enhanced the demonstration and research efforts as well as raise overall awareness of Dengue disease.
- In March 2021, Takeda Pharmaceutical Company Limited had announced that the European Medicines Agency (EMA) had accepted company’s filing package for its dengue vaccine candidate named TAK003. It is investigated for preventing dengue due to any dengue virus serotype in individual’s ages between 4 to 60 years. The submission of regulatory paperwork for our dengue vaccine candidate, TAK-003, is a significant step forward for those living in or travelling to dengue-affected areas. TAK-003, Takeda's tetravalent dengue vaccine candidate, is developed on a live-attenuated dengue serotype 2 virus that functions as the genetic "backbone" for all four vaccine viruses. TAK-003 produced immune responses against all four dengue serotypes in both seropositive and seronegative subjects, which lasted for 48 months following vaccination, according to clinical Phase 2 results in children and adolescents, and the vaccine was shown to be mainly safe and effective.
- In September 2021, The Central Drugs Standard Control Organization (CDSCO) granted Cosara Diagnostics Pvt Ltd regulatory license to manufacture and distribute the SARAGENE Dengue Test Kit. The SARAGENE Dengue Test Kit is an in vitro diagnostic test that uses Co-Diagnostics' proprietary a CoPrimers technology and is based on Real-Time Polymerase Chain Reaction Technology. It checks for the presence or absence of Dengue (Type 1, 2 4) ribonucleic acid (RNA) in serum or plasma from individuals who are suspected of having the virus.
Regional Analysis
Geographically, the countries covered in the dengue treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the Dominant Region in Dengue Treatment Market During the Forecast Period 2021 - 2028
North America will continue to dominate the dengue treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of largest consumer market along with high GDP and developed healthcare infrastructure in the region. Additionally, the rising number of outsourcing services and surging research and development activities in pharma and biotech sector will propel the market’s growth rate during the forecast period in this region.
Asia-Pacific is Estimated to be the Fastest Growing Region in Dengue Treatment Market the Forecast Period 2021 - 2028
Asia-Pacific is expected to grow during the forecast period as the demand for dengue treatment products is increasing very swiftly with urbanization and laboratory automation which is expected to propel the market's growth rate in this region. The Asia-Pacific dengue treatment market is likely to be dominated by China, which is one of the major countries in the dengue treatment industry.
COVID-19 Impact Analysis
The pandemic of COVID-19 had a significant influence on the dengue treatment market. In the early stages of infection, dengue viruses and the virus that causes COVID-19 (SARS-CoV-2) have comparable symptoms. As a result of the comparable symptoms of COVID-19 and dengue, a large section of the population underwent dengue testing, driving growth of dengue treatment market. Furthermore, during the COVID-19 pandemic, various regions throughout the world have reported an increase in dengue incidence.
Moreover, businesses across many industries have faced the effects of lockdown and government-imposed limitations as a result of the coronavirus. The private healthcare sector and health firms that rely on intimate personal contact with their customers have been severely impacted.
For More Detailed Information about the Dengue Treatment Market Report, Click Here – https://www.databridgemarketresearch.com/reports/global-dengue-treatment-market
